<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: materialize", fill: "#321414"},
{source: "1: materialize", target: "1: operations", fill: "#321414"},
{source: "1: operations", target: "1: materially", fill: "#321414"},
{source: "1: materialize", target: "2: market price", fill: "#e68fac"},
{source: "2: market price", target: "2: common stock could decline", fill: "#e68fac"},
{source: "2: market price", target: "13: may vary which could negatively affect", fill: "#e30b5d"},
{source: "13: may vary which could negatively affect", target: "13: market price", fill: "#e30b5d"},
{source: "13: market price", target: "13: common stock", fill: "#e30b5d"},
{source: "13: may vary which could negatively affect", target: "14: will continue", fill: "#3f00ff"},
{source: "14: will continue", target: "14: variation depending on factors such as", fill: "#3f00ff"},
{source: "14: variation depending on factors such as", target: "14: commencement completion", fill: "#3f00ff"},
{source: "14: commencement completion", target: "14: cancellation", fill: "#3f00ff"},
{source: "14: cancellation", target: "14: significant contracts", fill: "#3f00ff"},
{source: "14: significant contracts", target: "14: acquisitions", fill: "#3f00ff"},
{source: "14: acquisitions", target: "14: startup expenses", fill: "#3f00ff"},
{source: "14: startup expenses", target: "14: costs associated", fill: "#3f00ff"},
{source: "14: costs associated", target: "14: with integrating acquisitions", fill: "#3f00ff"},
{source: "14: will continue", target: "37: qualified personnel", fill: "#fefe22"},
{source: "37: qualified personnel", target: "37: pharmaceutical", fill: "#fefe22"},
{source: "37: pharmaceutical", target: "37: biotechnology fields", fill: "#fefe22"},
{source: "37: qualified personnel", target: "150: volatility", fill: "#e3ff00"},
{source: "150: volatility", target: "150: often been unrelated", fill: "#e3ff00"},
{source: "150: often been unrelated", target: "150: particular companies", fill: "#e3ff00"},
{source: "150: volatility", target: "START_HERE", fill: "#e3ff00"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Humanitarian</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price">Price</a></td>
      <td>A prince is a male ruler (ranked below a king, grand prince, and grand duke) or a male member of a monarch's or former monarch's family. Prince is also a title of nobility (often highest), often hereditary, in some European states.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_trend">Market trend</a></td>
      <td>A market trend is a perceived tendency of financial markets to move in a particular direction over time. These trends are classified as secular for long time frames, primary for medium time frames, and secondary for short time frames.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing_strategies">Pricing strategies</a></td>
      <td>A business can use a variety of pricing strategies when selling a product or service. To determine the most effective pricing strategy for a company, senior executives need to first identify the company's pricing position, pricing segment, pricing capability and their competitive pricing reaction strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_power">Market power</a></td>
      <td>In economics, market power refers to the ability of a firm to influence the price at which it sells a product or service by manipulating either the supply or demand of the product or service to increase economic profit. In other words, market power occurs if a firm does not face a perfectly elastic demand curve and can set its price (P) above marginal cost (MC) without losing revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_discrimination">Price discrimination</a></td>
      <td>Price discrimination is a microeconomic pricing strategy where identical or largely similar goods or services are sold at different prices by the same provider in different markets. Price discrimination is distinguished from product differentiation by the more substantial difference in production cost for the differently priced products involved in the latter strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_Chopper_and_Market_32_Supermarkets">Price Chopper and Market 32 Supermarkets</a></td>
      <td>Golub Corporation is an American supermarket operator. Headquartered in Schenectady, New York, it owns the chains Market 32 and Price Chopper Supermarkets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing">Pricing</a></td>
      <td>Pricing is the process whereby a business sets the price at which it will sell its products and services, and may be part of the business's marketing plan. In setting prices, the business will take into account the price at which it could acquire the goods, the manufacturing cost, the marketplace, competition, market condition, brand, and quality of product.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-price_competition">Non-price competition</a></td>
      <td>Non-price competition is a marketing strategy "in which one firm tries to distinguish its product or service from competing products on the basis of attributes like design and workmanship". It often occurs in imperfectly competitive markets because it exists between two or more producers that sell goods and services at the same prices but compete to increase their respective market shares through non-price measures such as marketing schemes and greater quality.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Volatility_(finance)">Volatility (finance)</a></td>
      <td>In finance, volatility (usually denoted by σ) is the degree of variation of a trading price series over time, usually measured by the standard deviation of logarithmic returns.\nHistoric volatility measures a time series of past market prices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_structure">Market structure</a></td>
      <td>Market structure, in economics, depicts how firms are differentiated and categorised based on the types of goods they sell (homogeneous/heterogeneous) and how their operations are affected by external factors and elements. Market structure makes it easier to understand the characteristics of diverse markets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Knowledge_acquisition">Knowledge acquisition</a></td>
      <td>Knowledge acquisition is the process used to define the rules and ontologies required for a knowledge-based system. The phrase was first used in conjunction with expert systems to describe the initial tasks associated with developing an expert system, namely finding and interviewing domain experts and capturing their knowledge via rules, objects, and frame-based ontologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy">Pharmacy</a></td>
      <td>Pharmacy is the clinical health science that links medical science with chemistry and it is charged with the discovery, production, disposal, safe and effective use, and control of medications and drugs. The practice of pharmacy requires excellent knowledge of drugs, their mechanism of action, side effects, interactions, mobility and toxicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_code">Pharmaceutical code</a></td>
      <td>Pharmaceutical codes are used in medical classification to uniquely identify medication. They may uniquely identify an active ingredient, drug system (including inactive ingredients and time-release agents) in general, or a specific pharmaceutical product from a specific manufacturer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sun_Pharma">Sun Pharma</a></td>
      <td>Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)  in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_lobby">Pharmaceutical lobby</a></td>
      <td>The pharmaceutical lobby refers to the representatives of pharmaceutical drug and biomedicine companies who engage in lobbying in favour of pharmaceutical companies and their products.\n\n\n== Political influence in the United States ==\nThe largest pharmaceutical companies and their two trade groups, Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Innovation Organization, lobbied on at least 1,600 pieces of legislation between 1998 and 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals">Janssen Pharmaceuticals</a></td>
      <td>Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson &amp; Johnson. It was founded in 1953 by Paul Janssen.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biotechnology">Biotechnology</a></td>
      <td>Biotechnology is "the integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular analogues for products and services". The term biotechnology was first used by Károly Ereky in 1919, meaning the production of products from raw materials with the aid of living organisms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_company">Public company</a></td>
      <td>A public company, publicly traded company, publicly held company, publicly listed company, or public limited company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (listed company), which facilitates the trade of shares, or not (unlisted public company).</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PRA International      ITEM 1A  RISK FACTORS       If  any  of  the  <font color="blue">following risks</font> <font color="blue">materialize</font>, our business, financial     condition, or results of <font color="blue">operations</font> could be <font color="blue">materially</font> harmed</td>
    </tr>
    <tr>
      <td>In that     case, the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> could decline</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business       Our contracts are <font color="blue"><font color="blue">generally</font> terminable on</font> little or no notice</td>
    </tr>
    <tr>
      <td><font color="blue">Termination     </font>of a large contract for services or <font color="blue">multiple contracts</font> for <font color="blue">services could</font>     <font color="blue"><font color="blue">adversely</font> affect</font> our revenue and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Clients terminate or <font color="blue">delay contracts</font> for various     reasons</td>
    </tr>
    <tr>
      <td>We  have  experienced <font color="blue">termination</font> or <font color="blue"><font color="blue">cancellation</font> by certain</font>     customers in the <font color="blue">ordinary course</font> of business</td>
    </tr>
    <tr>
      <td>The reasons more <font color="blue"><font color="blue">frequently</font> given</font> for <font color="blue">termination</font> include:         •  the failure of the product being tested to <font color="blue">satisfy safety</font> or efficacy     <font color="blue">requirements</font>;         •  unexpected or <font color="blue">undesired clinical</font> results of the product; and         •  the client’s decision to forego a <font color="blue">particular study</font></td>
    </tr>
    <tr>
      <td>Less <font color="blue">frequently</font>, <font color="blue">termination</font>s occur because of:         •  insufficient <font color="blue">patient enrollment</font> or <font color="blue">investigator recruitment</font>;         •  the client’s decision to downsize its <font color="blue">product <font color="blue">development</font> portfolios</font>;                                         18       _________________________________________________________________               •  the client’s dissatisfaction with our performance, including the     quality of <font color="blue">data provided</font> and our ability to <font color="blue">meet agreed upon schedules</font>; and         •  <font color="blue">production problems</font> resulting in shortages of the drug or required     <font color="blue">clinical supplies</font></td>
    </tr>
    <tr>
      <td>The loss or delay of a program or large contract or the loss or delay of     <font color="blue">multiple smaller contracts <font color="blue">could harm</font></font> our business because such <font color="blue">termination</font>s     could  lower  our  level  of staff utilization, which would reduce our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In  addition,  the <font color="blue">terminability</font> of our contracts puts     <font color="blue">increased pressure on</font> our quality control efforts, since not only can our     contracts be <font color="blue">terminated by clients as</font> a result of poor performance, but any     such <font color="blue">termination</font> also may affect our ability to obtain <font color="blue">future contracts from</font>     the <font color="blue">client involved</font> and, possibly, others among the companies that sponsor     trials</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>the  contracts included in our backlog are <font color="blue">generally</font>     terminable without cause, we do not believe that our backlog as of any date     is <font color="blue">necessarily</font> a <font color="blue">meaningful predictor</font> of future results</td>
    </tr>
    <tr>
      <td>Our quarterly operating results may vary, which could negatively affect the     <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our quarterly operating results have been and <font color="blue">will continue</font> to be subject to     variation, <font color="blue">depending on</font> factors such as the commencement, completion, or     <font color="blue">cancellation</font> of <font color="blue"><font color="blue">significant</font> contracts</font>, the timing of <font color="blue"><font color="blue">acquisition</font>s</font>, the mix     of contracted services, foreign exchange rate <font color="blue">fluctuations</font>, the timing of     start-up expenses for new offices and services, and the <font color="blue">costs associated</font>     with integrating <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>We have experienced, and expect to continue     experiencing, some <font color="blue">variations</font> in our <font color="blue">revenue due</font> to our customers’ budgetary     cycles</td>
    </tr>
    <tr>
      <td>As a result, we believe that quarterly <font color="blue">comparisons</font> of our financial     results  should  not  be  relied  upon  as an <font color="blue">indication</font> of our future     performance</td>
    </tr>
    <tr>
      <td>In addition, quarterly <font color="blue">volatility</font> in our operating results     could cause declines in the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">depend on</font> a limited number of clients and a loss of or <font color="blue">significant</font>     decrease in business <font color="blue">from them could affect</font> our business</td>
    </tr>
    <tr>
      <td>We have in the past and may in the <font color="blue">future derive</font> a <font color="blue">significant</font> portion of     our <font color="blue">service revenue from</font> a <font color="blue">relatively</font> limited number of clients that vary     from  year  to  year</td>
    </tr>
    <tr>
      <td>Our <font color="blue">relationships with</font> these <font color="blue">customers involve</font> a     substantial number of individual <font color="blue">arrangements detailing</font> the <font color="blue">particulars</font> of a     <font color="blue">given clinical <font color="blue">development</font></font> project and <font color="blue">often implicate different entities</font>,     <font color="blue">departments</font>, or <font color="blue">companies under common control</font></td>
    </tr>
    <tr>
      <td>Nevertheless, the loss of,     or a <font color="blue">significant</font> decrease in business from, one or more of these clients     <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Because most of our <font color="blue">clinical <font color="blue">development</font> service revenue</font> is from long-term     fixed-fee contracts, we <font color="blue">would lose money</font> in performing these contracts if     our costs of performing them were to exceed the fixed <font color="blue">fees payable</font> to us</td>
    </tr>
    <tr>
      <td>Because most of our <font color="blue">clinical <font color="blue">development</font> service revenue</font> is from long-term     fixed  price  contracts, we bear the risk of <font color="blue">cost overruns under</font> these     contracts</td>
    </tr>
    <tr>
      <td>If the costs of completing these projects exceed the fixed fees     for these projects, our business, <font color="blue">financial condition</font>, and operating results     could be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends on</font> our <font color="blue">senior <font color="blue"><font color="blue">management</font> team</font></font>, and the loss of any     member of the <font color="blue">team may harm</font> our business</td>
    </tr>
    <tr>
      <td>We believe our <font color="blue">success will</font> <font color="blue">depend on</font> the <font color="blue">continued <font color="blue">employment</font></font> of our senior     <font color="blue"><font color="blue">management</font> team</font></td>
    </tr>
    <tr>
      <td>“<font color="blue">Directors and Executive Officers </font>of the     Registrant — Executive Officers</td>
    </tr>
    <tr>
      <td>” This <font color="blue"><font color="blue">management</font> team</font> has <font color="blue">significant</font>     experience in the <font color="blue">administration</font> of a CRO If one or more members of our     <font color="blue">senior <font color="blue"><font color="blue">management</font> team</font></font> were unable or unwilling to continue in their present     positions, those <font color="blue">persons could</font> be <font color="blue">difficult</font> to replace and our business     could be harmed</td>
    </tr>
    <tr>
      <td>We do not currently maintain key person <font color="blue">life insurance</font>     <font color="blue">policies on</font> any of our employees</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">key employees</font> were to join a     <font color="blue">competitor</font> or to form a <font color="blue">competing company</font>, some of our <font color="blue">clients might choose</font>     to use the services of that <font color="blue">competitor</font> or <font color="blue">new company instead</font> of our own</td>
    </tr>
    <tr>
      <td>Furthermore,  clients  or  other <font color="blue">companies seeking</font> to develop in-house     <font color="blue">capabilities may hire away</font> some of our <font color="blue">senior <font color="blue">management</font></font> or <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td>In  addition,  although  we  have amended our <font color="blue">senior <font color="blue"><font color="blue">management</font> team</font></font>’s     <font color="blue">employment</font>  <font color="blue">agreements</font>  in  response  to  a  prior  challenge  of  our     non-<font color="blue">competition</font> provisions we <font color="blue">cannot assure</font> you that a <font color="blue">court would enforce</font>     the non-<font color="blue">competition</font> provisions in the amended <font color="blue">employment</font> <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________           If we are unable to recruit and retain <font color="blue">qualified personnel</font>, we may not be     able to expand our business or <font color="blue">remain <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">specialized scientific</font> nature of our business, we are highly     <font color="blue">dependent</font> upon qualified scientific, technical and <font color="blue">managerial personnel</font></td>
    </tr>
    <tr>
      <td>At     the  present time, <font color="blue">approximately</font> 28prca of our workforce holds at least a     master’s degree</td>
    </tr>
    <tr>
      <td>There is intense <font color="blue">competition</font> for <font color="blue">qualified personnel</font> in the     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> fields</font></td>
    </tr>
    <tr>
      <td>In the future, we may not be able     to attract and retain the <font color="blue">qualified personnel</font> <font color="blue">necessary</font> for the conduct and     <font color="blue">further <font color="blue">development</font></font> of our business</td>
    </tr>
    <tr>
      <td>The loss of the services of existing     personnel, as well as the failure to <font color="blue">recruit <font color="blue">additional</font> key scientific</font>,     technical, and <font color="blue">managerial personnel</font> in a timely manner, <font color="blue">could harm</font> our     ability  to  expand  our business and to <font color="blue">remain <font color="blue">competitive</font></font> in the CRO     industry</td>
    </tr>
    <tr>
      <td>Our  business  could  be  harmed if we are unable to manage our growth     <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td>We have experienced <font color="blue">rapid growth throughout</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We believe that     sustained  <font color="blue">growth places</font> a strain on operational, human, and financial     resources</td>
    </tr>
    <tr>
      <td>To manage our growth, we <font color="blue">must continue</font> to improve our operating     and <font color="blue">administrative systems</font> and to attract and retain <font color="blue">qualified <font color="blue">management</font></font>,     professional, scientific, and technical operating personnel</td>
    </tr>
    <tr>
      <td>We believe that     maintaining and <font color="blue">enhancing both</font> our systems and <font color="blue">personnel at reasonable cost</font>     are <font color="blue">instrumental</font> to our success in the CRO industry</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that  we  will be able to enhance our <font color="blue">current <font color="blue">technology</font></font> or obtain new     <font color="blue">technology</font> that will enable our systems to keep <font color="blue">pace with <font color="blue">development</font>s</font> and     the <font color="blue">sophisticated</font> needs of our clients</td>
    </tr>
    <tr>
      <td>The nature and pace of our growth     introduces risks associated with quality control and <font color="blue">client dissatisfaction</font>     due  to  delays in performance or other problems</td>
    </tr>
    <tr>
      <td>In addition, foreign     <font color="blue">operations</font> involve the <font color="blue"><font color="blue">additional</font> risks</font> of <font color="blue"><font color="blue">assimilating</font> <font color="blue">differences</font></font> in     foreign business practices, hiring and retaining <font color="blue">qualified personnel</font>, and     <font color="blue">overcoming language barriers</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that with any future     <font color="blue"><font color="blue">acquisition</font>s</font>, we will assume the problems of the acquired entity</td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>past <font color="blue"><font color="blue">acquisition</font>s</font> have not resulted in any <font color="blue">significant</font> integration problems,     we anticipate <font color="blue"><font color="blue">additional</font> growth</font> in the future and we may face these types of     issues</td>
    </tr>
    <tr>
      <td>Our exposure to <font color="blue">exchange rate <font color="blue">fluctuations</font> could <font color="blue">negatively impact</font></font> our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We derived <font color="blue">approximately</font> 42prca of our <font color="blue">consolidated service revenue</font> in 2005     from  our  <font color="blue">operations</font> outside of the United States, <font color="blue">primarily from</font> our     <font color="blue">operations</font> in Europe and Canada, where <font color="blue">significant</font> amounts of our revenues     and expenses are recorded in <font color="blue">local currency</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial statements</font> are     presented in US dollars</td>
    </tr>
    <tr>
      <td>Accordingly, changes in <font color="blue">currency exchange rates</font>,     <font color="blue">particularly among</font> the Euro, British pound, and the <font color="blue">Canadian </font>dollar, and the     US dollar, may cause <font color="blue">fluctuations</font> in our reported financial results that     could be material</td>
    </tr>
    <tr>
      <td>In addition, a portion of our contracts with our clients are <font color="blue">denominated</font> in     currencies other than the currency in which we <font color="blue">incur expenses</font> related to     those contracts</td>
    </tr>
    <tr>
      <td>In Canada, our contracts <font color="blue">generally</font> provide for invoicing     clients in US dollars, but our expenses are <font color="blue">generally</font> incurred in <font color="blue">Canadian </font>    dollars</td>
    </tr>
    <tr>
      <td>Where expenses are incurred in currencies other than those in which     contracts are priced, <font color="blue">fluctuations</font> in the <font color="blue">relative value</font> of those currencies     <font color="blue">could harm</font> our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In  January,  2006,  we <font color="blue">entered into multiple foreign currency hedging</font>     <font color="blue"><font color="blue">transaction</font>s</font> to <font color="blue">mitigate exposure</font> to <font color="blue">movements between</font> the US dollar and     the British pound and the US dollar and Euro</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">certain risks associated with</font> our foreign <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have offices and conduct business <font color="blue">on six continents</font></td>
    </tr>
    <tr>
      <td>Certain risks are     inherent in these international <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The risks related to our foreign <font color="blue">operations</font> that we more often face in the     <font color="blue">normal course</font> of business include:         •  tax rates in <font color="blue">certain foreign countries may exceed</font> those in the United     States and foreign earnings may be subject to withholding <font color="blue">requirements</font> or     the imposition of tariffs, exchange controls, or other <font color="blue">restrictions</font>,     including <font color="blue">restrictions</font> on repatriation; and         •  <font color="blue">general economic</font> and <font color="blue">political conditions</font> in countries where we operate     may have an adverse effect on our <font color="blue">operations</font> in those countries</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________             Less <font color="blue">frequently</font>, we encounter the <font color="blue">following risks</font>:         •  <font color="blue">foreign customers may</font> have <font color="blue">longer payment cycles than customers</font> in the     United States;         •  we may have <font color="blue">difficult</font>y complying with a variety of <font color="blue">foreign laws</font> and     <font color="blue">regulations</font>, some of <font color="blue">which may conflict with</font> <font color="blue">United States </font>law;         •  the <font color="blue">difficult</font>y of enforcing <font color="blue">agreements</font> and <font color="blue">collecting receivables</font>     <font color="blue">through certain foreign legal systems</font>; and         •  the <font color="blue">difficult</font>ies associated with managing a large <font color="blue">organization spread</font>     <font color="blue">throughout various countries</font></td>
    </tr>
    <tr>
      <td>While  we  have  not  experienced  any <font color="blue">major problems</font> to date with the     <font color="blue">acquisition</font> or operation of our <font color="blue">foreign entities</font>, we may in the future     <font color="blue">encounter <font color="blue">certain limitations</font> inherent</font> in the carrying out of clinical     <font color="blue">development</font>  trials  <font color="blue">internationally</font>, including <font color="blue">establishing effective</font>     <font color="blue">communications</font>,  operating  in  various  time  zones, and <font color="blue">dealing with</font>     incompatible <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>As  we  continue  to expand our business globally, our <font color="blue">success will</font> be     <font color="blue">dependent</font>, in part, on our ability to anticipate and <font color="blue">effectively</font> manage     these and other risks associated with foreign <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>     you that these and other <font color="blue">factors will</font> not have a material adverse effect on     our  international <font color="blue">operations</font> or our business, <font color="blue">financial condition</font>, or     results of <font color="blue">operations</font> as a whole</td>
    </tr>
    <tr>
      <td>We <font color="blue">provide services</font> to <font color="blue">emerging companies which may</font> be unable to pay us</td>
    </tr>
    <tr>
      <td>We <font color="blue">incur costs</font> in providing drug <font color="blue">development</font> services to our clients before     we  are  paid</td>
    </tr>
    <tr>
      <td>We  provide drug <font color="blue">development</font> services to bio<font color="blue">technology</font>     companies, many of which are early-stage companies with <font color="blue">relatively</font> limited     <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>If any of these companies were to cease <font color="blue">operations</font>     before paying us for our services, or are <font color="blue">otherwise unable</font> to pay, our     results of <font color="blue">operations</font> could suffer</td>
    </tr>
    <tr>
      <td>We  have  a <font color="blue">significant</font> amount of <font color="blue">goodwill on</font> our <font color="blue">balance sheet</font>, and a     downturn in our business or <font color="blue">industry could</font> require us to take a charge to     earnings, which may negatively affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our  balance  sheet  reflects  a <font color="blue">significant</font> amount of goodwill, which     represents dlra106dtta7 million, or <font color="blue">approximately</font> 32dtta4prca of our <font color="blue">total assets as</font> of     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We review the amount of our goodwill whenever events or     changes in <font color="blue">circumstances indicate</font> that the carrying amount of the goodwill     may not be <font color="blue">fully recoverable</font></td>
    </tr>
    <tr>
      <td>To determine <font color="blue">recoverability</font>, we annually     compare the <font color="blue">fair value</font> of our reporting unit (which is our company) to its     carrying  value</td>
    </tr>
    <tr>
      <td>Although no event has occurred to date impairing our     goodwill, there is a <font color="blue">possibility</font> that the carrying amount of the goodwill     could be impaired if there is a downturn in our business or our industry or     other <font color="blue">factors affect</font> the <font color="blue">fair value</font> of our business, in which case a charge     to earnings would become <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>Our business depends <font color="blue">significant</font>ly on the <font color="blue">continued effectiveness</font> of our     information <font color="blue">technology</font> infrastructure, and failures of such <font color="blue">technology</font> could     harm our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>To  remain  <font color="blue">competitive</font>  in  our  industry, we <font color="blue">must employ</font> information     <font color="blue">technologies</font> that capture, manage, and analyze the large streams of data     generated  during  our  clinical  trials in <font color="blue"><font color="blue">compliance with</font> applicable</font>     <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In addition, because we <font color="blue">provide services</font> on a     <font color="blue">global basis</font>, we <font color="blue">rely extensively on</font> our <font color="blue">technology</font> to allow the <font color="blue">concurrent</font>     conduct  of  studies  and  work  <font color="blue">sharing around</font> the world</td>
    </tr>
    <tr>
      <td>As with all     information <font color="blue">technology</font>, our system is vulnerable to <font color="blue">potential damage</font> or     interruptions from fires, blackouts, tele<font color="blue">communications</font> failures, and other     unexpected events, as well as to break-ins, sabotage, or <font color="blue">intentional</font> acts of     vandalism</td>
    </tr>
    <tr>
      <td>Given the extensive reliance of our business on this <font color="blue">technology</font>,     any substantial <font color="blue">disruption</font> or resulting loss of data that is not avoided or     corrected by our backup measures <font color="blue">could harm</font> our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business could be harmed if we <font color="blue">cannot <font color="blue">successfully</font> integrate future</font>     <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>We review <font color="blue">acquisition</font> <font color="blue">candidates</font> in the <font color="blue">ordinary course</font> of our business</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>involve numerous risks, including the <font color="blue">expenses incurred</font> in     <font color="blue">connection</font>  with  the  <font color="blue">acquisition</font>,  the  <font color="blue">difficult</font>ies in <font color="blue">assimilating</font>     <font color="blue">operations</font>, the diversion of <font color="blue">management</font>’s attention from other business     concerns, and the <font color="blue">potential loss</font> of <font color="blue">key employees</font> of the acquired company</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font> of  foreign  companies  involve  the <font color="blue"><font color="blue">additional</font> risks</font> of     <font color="blue"><font color="blue">assimilating</font> <font color="blue">differences</font></font> in                                         21       _________________________________________________________________           foreign business practices, hiring and retaining <font color="blue">qualified personnel</font>, and     <font color="blue">overcoming language barriers</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we <font color="blue">will <font color="blue">successfully</font></font>     integrate future <font color="blue"><font color="blue">acquisition</font>s</font> into our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  compete  in  a  highly <font color="blue">competitive</font> market and if we do not compete     <font color="blue">successfully</font> our business could be harmed</td>
    </tr>
    <tr>
      <td>We <font color="blue">compete against</font> other CROs, in-house <font color="blue">development</font> at large <font color="blue">pharmaceutical</font>     companies, and, to a lesser extent, universities and <font color="blue">teaching hospitals</font></td>
    </tr>
    <tr>
      <td>Our     principal  <font color="blue">competitor</font>s  are  traditional CROs, including Charles River     Laboratories International, Inc, Covance Inc, ICON plc, INC Research,     Inc, Kendle International Inc, MDS Pharma Services, PAREXEL International     Corporation, Pharmaceutical Product Development, Inc, SFBC International,     Inc, Quintiles Transnational Corp, United BioSource Corporation, and     United  HealthCare Corporation</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">competitor</font>s have greater     capital and other <font color="blue">resources than</font> we do at the present time</td>
    </tr>
    <tr>
      <td>As a result of     <font color="blue">competitive</font> pressures and the potential for economies of scale, the industry     continues to experience <font color="blue">consolidation</font></td>
    </tr>
    <tr>
      <td>This trend, as well as a trend by     <font color="blue">pharmaceutical</font> companies and other clients to <font color="blue">limit outsourcing</font> to fewer     <font color="blue">organizations</font>, in some <font color="blue">cases through <font color="blue">preferred vendor</font> relationships</font>, is     likely to result in <font color="blue">increased worldwide <font color="blue">competition</font> among</font> the larger CROs     for clients and <font color="blue">acquisition</font> <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We believe that major <font color="blue">pharmaceutical</font>     and  bio<font color="blue">technology</font>  companies  have  been  developing <font color="blue">preferred vendor</font>     <font color="blue">relationships with</font> full-service CROs, <font color="blue">effectively</font> excluding other CROs from     the <font color="blue">bidding process</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">preferred vendor</font> relationships are not <font color="blue">contractual</font>     and are subject to change at any time</td>
    </tr>
    <tr>
      <td>We <font color="blue">may find reduced access</font> to certain     potential  clients  due  to  preferred  <font color="blue">vendor arrangements with</font> other     <font color="blue">competitor</font>s</td>
    </tr>
    <tr>
      <td>In addition, the CRO industry has attracted the attention of     the <font color="blue"><font color="blue">investment</font> community</font>, and increased potential <font color="blue">financial resources</font> are     likely to lead to <font color="blue">increased <font color="blue">competition</font> among</font> CROs</td>
    </tr>
    <tr>
      <td>There are <font color="blue">few barriers</font>     to entry for small, limited-service entities entering the CRO industry, and     these  <font color="blue">entities also may compete with established</font> CROs for clients</td>
    </tr>
    <tr>
      <td>We     address  the <font color="blue">competition</font> in our <font color="blue">industry by continuing</font> to focus on the     quality  of  our  services, maintaining our <font color="blue">therapeutic expertise</font>, and     investing  in  our  <font color="blue">quality <font color="blue">management</font> system</font></td>
    </tr>
    <tr>
      <td>Nevertheless, increased     <font color="blue">competition</font> may lead to price and other forms of <font color="blue">competition</font> that <font color="blue">could harm</font>     our business</td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry       Our business could be harmed if the companies in the <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> <font color="blue">industries</font> to whom we offer our <font color="blue">services reduce</font> their research     and <font color="blue">development</font> activities or reduce the extent to which they outsource     clinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends upon</font> the ability and <font color="blue">willingness</font> of companies in the     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> <font color="blue">industries</font> to continue to <font color="blue">spend on research</font>     and <font color="blue">development</font> at rates close to or <font color="blue">at historical levels</font> and to outsource     the services we provide</td>
    </tr>
    <tr>
      <td>We are therefore subject to risks, uncertainties,     and trends thataffect companies in these <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>For example, we have     benefited  to  date from the <font color="blue">increasing tendency</font> of <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font>  companies  to  outsource  both small and large clinical     <font color="blue">development</font>  projects</td>
    </tr>
    <tr>
      <td>Conversely,  mergers  and  <font color="blue"><font color="blue">acquisition</font>s</font> in the     <font color="blue">pharmaceutical</font>  and bio<font color="blue">technology</font> <font color="blue">industries</font> could have an <font color="blue">impact on</font> a     company’s continued ability to <font color="blue">outsource such</font> projects to CROs</td>
    </tr>
    <tr>
      <td>Any general     downturn in the <font color="blue">pharmaceutical</font> or bio<font color="blue">technology</font> <font color="blue">industries</font>, any reduction in     research and <font color="blue">development</font> spending by companies in these <font color="blue">industries</font>, or any     expansion of their in-house <font color="blue">development</font> capabilities could <font color="blue">materially</font> harm     our business, <font color="blue">financial condition</font>, and operating results</td>
    </tr>
    <tr>
      <td>Our business and the <font color="blue">businesses</font> of our customers are subject to extensive     regulation, and our results of <font color="blue">operations</font> could be harmed if <font color="blue">regulatory</font>     standards change <font color="blue">significant</font>ly or if we fail to maintain <font color="blue">compliance with</font>     evolving, complex <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Laws and <font color="blue">regulations</font> regarding the <font color="blue">development</font> and approval of drug and     <font color="blue">biological products</font> have become <font color="blue">increasingly</font> stringent in both the United     States and foreign <font color="blue">jurisdictions</font>, resulting in a need for more complex and     <font color="blue">often larger clinical studies</font></td>
    </tr>
    <tr>
      <td>We believe that these trends have created an     <font color="blue">increased demand</font> for CRO <font color="blue">services from which</font> our business benefits</td>
    </tr>
    <tr>
      <td><font color="blue">Human     </font><font color="blue">pharmaceutical</font> products and <font color="blue">biological products</font> are subject to rigorous     regulation  by  the  US government (principally by the Food and Drug     Administration, or FDA), and by foreign <font color="blue">governments</font> if products are tested     or marketed abroad</td>
    </tr>
    <tr>
      <td>A <font color="blue">relaxation</font> of the scope of <font color="blue">regulatory</font> <font color="blue">requirements</font>,     such as                                         22       _________________________________________________________________           the <font color="blue">introduction</font> of <font color="blue">simplified <font color="blue">marketing applications</font></font> for <font color="blue">pharmaceutical</font>s     and biologics, could decrease the business <font color="blue"><font color="blue">opportunities</font> available</font> to us</td>
    </tr>
    <tr>
      <td>In addition, because we offer services relating to the conduct of clinical     trials and the <font color="blue">preparation</font> of <font color="blue">marketing applications</font>, we are required to     comply  with applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> governing, among other     things, the design, conduct, performance, monitoring, auditing, recording,     analysis, and reporting of these trials</td>
    </tr>
    <tr>
      <td>In the United States, the FDA     governs these <font color="blue">activities pursuant</font> to the agency’s Good Clinical Practice, or     GCP, <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>A failure to maintain <font color="blue">compliance with</font> the GCP or other     applicable <font color="blue">regulations</font> could lead to a variety of sanctions, including,     among other things, and <font color="blue">depending on</font> the nature of the violation and the     type of <font color="blue">product involved</font>, the suspension or <font color="blue">termination</font> of a <font color="blue">clinical study</font>,     civil penalties, criminal prosecutions, or <font color="blue">debarment from assisting</font> in the     submission of <font color="blue">new drug applications</font>, or NDAs</td>
    </tr>
    <tr>
      <td>While we monitor our clinical     trials to test for <font color="blue"><font color="blue">compliance with</font> applicable</font> laws and <font color="blue">regulations</font> in the     United  States and foreign <font color="blue">jurisdictions</font> in which we operate, and have     adopted  standard  operating  procedures  that are designed to satisfy     <font color="blue">regulatory</font>   <font color="blue">requirements</font>,  our  business  spans  multiple  <font color="blue">regulatory</font>     <font color="blue">jurisdictions</font> with varying, complex <font color="blue">regulatory</font> <font color="blue">frameworks</font>, and therefore we     <font color="blue">cannot assure</font> you that our systems will ensure compliance in every instance     in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Circumstances </font>beyond our <font color="blue">control could</font> cause the CRO industry to suffer     <font color="blue">reputational</font> or other harm that could result in an industry-wide reduction     in demand for CRO services, which <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Demand for our services may be affected by <font color="blue"><font color="blue">perception</font>s</font> of our customers     regarding the CRO <font color="blue">industry as</font> a whole</td>
    </tr>
    <tr>
      <td>For example, other CROs could engage     in conduct that could render our customers less willing to do business with     us or any <font color="blue">CRO Although </font>to date no event has occurred causing industry-wide     <font color="blue">reputational</font>  harm, one or more CROs could engage in or fail to detect     malfeasance, such as inadequately monitoring sites, producing <font color="blue">inaccurate</font>     <font color="blue">databases</font> or analysis, falsifying patient records, and performing incomplete     lab work, or take other actions that would reduce the confidence of our     customers  in  the  CRO  industry</td>
    </tr>
    <tr>
      <td>As  a  result,  the <font color="blue">willingness</font> of     <font color="blue">pharmaceutical</font>  and  bio<font color="blue">technology</font> companies to outsource research and     <font color="blue">development</font> services to CROs <font color="blue">could diminish</font> and our business <font color="blue">could thus</font> be     harmed <font color="blue">materially</font> by events outside our control</td>
    </tr>
    <tr>
      <td>If we <font color="blue">incur <font color="blue">liability</font></font> for <font color="blue">hazardous</font> material <font color="blue">contamination</font>, our business     would be harmed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">clinical pharmacology</font> unit <font color="blue">conducts activities</font> that have involved, and     <font color="blue">may continue</font> to involve, the <font color="blue">controlled use</font> of <font color="blue">hazardous</font> materials and the     creation of <font color="blue">hazardous</font> substances, including <font color="blue">medical waste</font> and other highly     <font color="blue">regulated substances</font></td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">safety procedures</font> for     handling the disposal of <font color="blue">such materials comply with</font> the <font color="blue">standards prescribed</font>     by state and <font color="blue">federal laws</font> and <font color="blue">regulations</font>, our <font color="blue">operations</font> nevertheless pose     the risk of <font color="blue">accident</font>al <font color="blue">contamination</font> or <font color="blue">injury from</font> these materials and the     creation of <font color="blue">hazardous</font> substances, including <font color="blue">medical waste</font> and other highly     <font color="blue">regulated substances</font></td>
    </tr>
    <tr>
      <td>In the event of such an <font color="blue">accident</font>, we could be held     liable for damages and cleanup costs which, to the extent not <font color="blue">covered by</font>     <font color="blue">existing insurance</font> or indemnification, <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>In addition,     other  adverse  effects  could  result  from  such<font color="blue">liability</font>, including     <font color="blue">reputational</font>  damage resulting in the loss of <font color="blue">additional</font> business from     <font color="blue">certain clients</font></td>
    </tr>
    <tr>
      <td>Our business could be <font color="blue">materially</font> harmed if we were required     to <font color="blue">pay damages beyond</font> the level of any <font color="blue">insurance coverage</font> that may be in     effect</td>
    </tr>
    <tr>
      <td>To date, we have not been the subject of any <font color="blue">investigations</font> or     claims related to the <font color="blue">controlled use</font> of <font color="blue">hazardous</font> materials and the creation     of <font color="blue">hazardous</font> substances</td>
    </tr>
    <tr>
      <td>Our  services  are  subject  to  <font color="blue">evolving industry standards</font> and rapid     <font color="blue">technological</font> changes</td>
    </tr>
    <tr>
      <td>The  markets  for  our  services are <font color="blue">characterized by rapidly</font> changing     <font color="blue">technology</font>, <font color="blue">evolving industry standards</font> and frequent <font color="blue">introduction</font> of new and     <font color="blue">enhanced services</font></td>
    </tr>
    <tr>
      <td>To succeed, we <font color="blue">must continue</font> to <font color="blue">introduce <font color="blue">new services</font> on</font>     a timely and cost-effective basis to meet evolving customer <font color="blue">requirements</font>,     while achieving <font color="blue">market acceptance</font> for these <font color="blue">new services</font></td>
    </tr>
    <tr>
      <td>Additionally, we     <font color="blue">must continue</font> to enhance our <font color="blue">existing services</font> and to <font color="blue">successfully</font> integrate     <font color="blue">new services</font> with those already being offered</td>
    </tr>
    <tr>
      <td>It is imperative that we     respond to <font color="blue">emerging industry standards</font> and other <font color="blue">technological</font> changes</td>
    </tr>
    <tr>
      <td>If     we fail to make the <font color="blue">necessary</font> enhancements to our business, systems and     products to keep pace with <font color="blue">evolving industry standards</font>, our <font color="blue">competitive</font>     position and results of <font color="blue">operations</font> may suffer</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________           Our <font color="blue">clinical research services</font> create a risk of <font color="blue">liability</font> and, if we are     required to pay damages or to bear the costs of defending any claim not     <font color="blue">covered by</font> <font color="blue">contractual</font> indemnity or insurance, this could cause material     harm to our business</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">research services involve</font> the testing of new drugs, biologics, and     <font color="blue">devices on human volunteers</font></td>
    </tr>
    <tr>
      <td>This testing creates risks of <font color="blue">liability</font> for     personal  injury,  sickness  or death of patients resulting from their     <font color="blue">participation</font>  in  the study</td>
    </tr>
    <tr>
      <td>These risks include, among other things,     <font color="blue">unforeseen adverse</font> side effects, improper application or <font color="blue">administration</font> of a     new drug, biologic, or device, and the <font color="blue">professional malpractice</font> of medical     <font color="blue">care providers</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">volunteer patients already</font> are <font color="blue">seriously ill</font> and are at     <font color="blue">heightened risk</font> of <font color="blue">future illness</font> or death</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection</font> with our provision     of <font color="blue">contract research services</font>, we <font color="blue">contract with physicians</font> to serve as     <font color="blue">investigators</font> in <font color="blue">conducting <font color="blue">clinical trials</font> on human volunteers</font></td>
    </tr>
    <tr>
      <td>Although we     do not believe we are <font color="blue">legally accountable</font> for the <font color="blue">medical care</font> rendered by     <font color="blue">third party</font> <font color="blue">investigators</font>, it is possible that we could be held liable for     the claims and expenses arising from any <font color="blue">professional malpractice</font> of the     <font color="blue">investigators</font> with whom we contract in the event of <font color="blue">personal injury</font> to or     death of <font color="blue">persons participating</font> in <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We also could be held     liable for errors or omissions in <font color="blue">connection</font> with the services we perform or     for the <font color="blue">general risks associated with</font> our Phase I <font color="blue">facility</font> including, but     not  limited to, <font color="blue">adverse reactions</font> to the <font color="blue">administration</font> of drugs</td>
    </tr>
    <tr>
      <td>Our     business could be <font color="blue">materially</font> harmed if we were required to pay damages or     bear the costs of defending any claim outside the scope of, or in excess of,     the <font color="blue">contractual</font> indemnification provided by our customer that is beyond the     level of any <font color="blue">insurance coverage</font> that may be in effect, or if an <font color="blue">indemnifying</font>     party does not fulfill its <font color="blue">indemnification obligations</font></td>
    </tr>
    <tr>
      <td>Health  care  industry  reform  <font color="blue">could reduce</font> or eliminate our business     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">health care industry</font> is subject to changing political, economic, and     <font color="blue">regulatory</font> influences that may affect the <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>In recent years, several comprehensive health care reform     proposals were introduced in the <font color="blue">United States </font>Congress</td>
    </tr>
    <tr>
      <td>The intent of the     proposals was, <font color="blue">generally</font>, to <font color="blue">expand health care coverage</font> for the uninsured     and  reduce the growth of <font color="blue">total health care expenditures</font></td>
    </tr>
    <tr>
      <td>In addition,     foreign  <font color="blue">governments</font>  may  also undertake <font color="blue">health care reforms</font> in their     <font color="blue">respective countries</font></td>
    </tr>
    <tr>
      <td>These reforms, if adopted, would make the <font color="blue">development</font>     of <font color="blue">new drugs less profitable</font> for our customers, and <font color="blue">could reduce</font> their     research and <font color="blue">development</font> budgets</td>
    </tr>
    <tr>
      <td>Business <font color="blue"><font color="blue">opportunities</font> available</font> to us     could decrease <font color="blue">materially</font> if the <font color="blue">implementation</font> of <font color="blue">government health care</font>     reform  <font color="blue">adversely</font>  affects  research  and  <font color="blue">development</font> expenditures by     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies</td>
    </tr>
    <tr>
      <td>Risks Related to Our Common Stock       The price of our <font color="blue">common stock</font> may fluctuate <font color="blue">significant</font>ly, and you could     lose all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> is likely to be volatile, and such     <font color="blue"><font color="blue">volatility</font> could prevent</font> you from being able to sell your shares at or above     the price you paid for your shares</td>
    </tr>
    <tr>
      <td>The stock market, and the stock of     companies in our industry in particular, has experienced <font color="blue">volatility</font>, and     this <font color="blue">volatility</font> has <font color="blue">often been unrelated</font> to the operating performance of     <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>Wide <font color="blue">fluctuations</font> in the <font color="blue">trading price</font> or volume of     our  shares of <font color="blue">common stock</font> could be caused by many factors, including     factors relating to our business or to investor <font color="blue">perception</font> of our business     (including changes in financial estimates and <font color="blue">recommendations by financial</font>     analysts  who follow us), but also factors relating to (or relating to     investor  <font color="blue">perception</font>  of)  the drug <font color="blue">development</font> services industry, the     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> <font color="blue">industries</font>, or the economy in general</td>
    </tr>
    <tr>
      <td>Thus, the price of our <font color="blue">common stock</font> could fluctuate based upon factors that     have little or nothing to do with our company, and the <font color="blue">fluctuations</font> could     result in a material reduction in our stock price</td>
    </tr>
    <tr>
      <td>The sale of a substantial number of our shares of <font color="blue">common stock</font> in the public     market <font color="blue">could reduce</font> the <font color="blue">market price</font> of our shares, which in turn could     <font color="blue">negatively impact</font> your <font color="blue">investment</font> in us</td>
    </tr>
    <tr>
      <td>Future sales of a substantial number of shares of our <font color="blue">common stock</font> in the     <font color="blue">public market</font> (or the <font color="blue">perception</font> that <font color="blue">such sales may</font> occur) <font color="blue">could reduce</font> our     stock price and <font color="blue">could impair</font> our ability to <font color="blue"><font color="blue">raise capital</font> through future</font>     sales  of  our  equity  securities</td>
    </tr>
    <tr>
      <td>As  of  January 31, 2006, we have     22cmam934cmam871 shares  of  common  stock  issued and outstanding, of which     14cmam071cmam373 shares of our <font color="blue">common stock</font> are available for sale in the public     market and an                                         24       _________________________________________________________________           <font color="blue">additional</font> 8cmam863cmam498 are available for sale in the <font color="blue">public market</font> at various     times (subject, in some cases, to <font color="blue">volume limitations under</font> Rule 144)</td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">stockholders</font> that <font color="blue">collectively</font> own 3cmam591cmam718 shares of our common     stock have <font color="blue">registration rights with respect</font> to their shares that may be     <font color="blue">exercised at</font> any time, subject to <font color="blue">certain limitations</font></td>
    </tr>
    <tr>
      <td>We and our <font color="blue">stockholders</font> are able to sell our shares in the <font color="blue">public market</font>,     subject to <font color="blue">restrictions</font> on shares held <font color="blue">by affiliates</font></td>
    </tr>
    <tr>
      <td>Sales of a substantial     number of such shares (or the <font color="blue">perception</font> that <font color="blue">such sales may</font> occur) could     cause our share price to fall</td>
    </tr>
    <tr>
      <td>Our principal <font color="blue">stockholders</font> hold shares of our     <font color="blue">common stock</font> in which they have a very large <font color="blue">unrealized gain</font>, and these     <font color="blue">stockholders</font> may wish, to the extent they <font color="blue">may permissibly</font> do so, to realize     some or all of that gain <font color="blue">relatively</font> quickly by selling some or all of their     shares</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also issue shares</font> of our <font color="blue">common stock</font> from time to time as     <font color="blue">consideration</font>  for  future  <font color="blue"><font color="blue">acquisition</font>s</font>  and <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>If any such     <font color="blue">acquisition</font> or <font color="blue">investment</font> is <font color="blue">significant</font>, the number of shares that we may     issue may in turn be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">may grant registration</font>     <font color="blue">rights covering</font> those shares in <font color="blue">connection</font> with any such <font color="blue"><font color="blue">acquisition</font>s</font> and     <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>In addition, we may sell, or register to sell on a delayed or <font color="blue">continuous</font>     basis  under  Rule 415, <font color="blue">additional</font> shares of our <font color="blue">common stock</font> or other     securities to <font color="blue">raise capital</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the size of <font color="blue">future issuances</font>     or the effect, if any, that they may have on the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>The issuance and sales of substantial amounts of <font color="blue">common stock</font> or     other securities, or the <font color="blue">perception</font> that <font color="blue">such issuances</font> and sales may occur,     could <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">implemented certain provisions</font> that could make any change in our     board of <font color="blue">directors</font> or in control of our company more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">certificate</font> of incorporation, our bylaws and <font color="blue">Delaware </font>law contain     provisions, such as provisions authorizing, without a vote of <font color="blue">stockholders</font>,     the issuance of one or more series of <font color="blue">preferred stock</font>, that could make it     <font color="blue">difficult</font> or expensive for a <font color="blue">third party</font> to pursue a <font color="blue">tender offer</font>, change in     control or <font color="blue">takeover attempt</font> that is <font color="blue">opposed by</font> our <font color="blue">management</font> and board of     <font color="blue">directors</font>  even  if  such  a  <font color="blue">transaction</font>  would  be <font color="blue">beneficial</font> to our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We also have a <font color="blue">staggered board</font> of <font color="blue">directors</font> that could make it     more <font color="blue">difficult</font> for <font color="blue">stockholders</font> to change the <font color="blue">composition</font> of our board of     <font color="blue">directors</font>  in  any  one  year</td>
    </tr>
    <tr>
      <td>These  anti-takeover  <font color="blue">provisions could</font>     <font color="blue">substantially</font>  impede the ability of public <font color="blue">stockholders</font> to change our     <font color="blue">management</font> and board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Our largest <font color="blue">stockholders</font> continue to have <font color="blue">significant</font> influence over us, and     they may make <font color="blue">decisions with which</font> you disagree</td>
    </tr>
    <tr>
      <td>Genstar Capital Partners III, LP, Baron Capital Group, Inc, Wasatch     Advisors,  Inc,  FMR Corporation, Artisan Investment Corporation, and     Waddell &amp;  Reed  Financial <font color="blue">beneficial</font>ly own <font color="blue">approximately</font> 45dtta1prca of the     <font color="blue">outstanding shares</font> of <font color="blue">common stock</font> (or <font color="blue">approximately</font> 43dtta1prca of the shares of     <font color="blue">common stock</font> on a <font color="blue">diluted basis</font>)</td>
    </tr>
    <tr>
      <td>If these <font color="blue">stockholders</font> choose to act in     <font color="blue">concert on</font> any action requiring <font color="blue">stockholder approval</font>, they could have a     <font color="blue">significant</font> influence on the outcome of <font color="blue">such action</font></td>
    </tr>
    <tr>
      <td>The interests of these     current <font color="blue">stockholders</font> may conflict with your interests, and we <font color="blue">cannot assure</font>     you that they <font color="blue">will resolve</font> any <font color="blue">such conflict</font> in a <font color="blue">manner with which</font> you     agree</td>
    </tr>
    <tr>
      <td>In addition, this <font color="blue">concentration</font> of <font color="blue">ownership could</font> have the effect of     <font color="blue">discouraging</font>  potential  takeover  attempts  and  may make <font color="blue">attempts by</font>     <font color="blue">stockholders</font> to change our <font color="blue">management</font> more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Because we typically have not <font color="blue">paid dividends</font> and do not anticipate paying     <font color="blue">dividends on</font> our <font color="blue">common stock</font> for the <font color="blue">indefinite future</font>, you should not     expect to receive <font color="blue">dividends on</font> shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have no present plans to <font color="blue">pay cash dividends</font> to our <font color="blue">stockholders</font> and, for     the <font color="blue">indefinite future</font>, intend to retain all of our earnings for use in our     business</td>
    </tr>
    <tr>
      <td>The <font color="blue">declaration</font> of any <font color="blue">future dividends by us</font> is within the     <font color="blue">discretion</font> of our board of <font color="blue">directors</font> and will be <font color="blue">dependent</font> on our earnings,     <font color="blue">financial condition</font>, and capital <font color="blue">requirements</font>, as well as any other factors     deemed  <font color="blue">relevant by</font> our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Although we paid a special     dividend to our <font color="blue">stockholders</font> in January 2004, the dividend was an unusual     event that we do not expect to recur</td>
    </tr>
    <tr>
      <td>Accordingly, you should not expect to     receive <font color="blue">dividends on</font> shares of our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>